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elc@mail.xjtu.edu.Abstract The epidermal growth factor receptors (EGFRs) in some tumor cells are signiﬁcant
targets for drug discovery. In this work, we have developed an EGFR cell membrane
chromatography and online high performance liquid chromatography/mass spectrometry system
for screening active component from Rhizoma Polygoni Cuspidati. As a result, resveratrol from
Rhizoma Polygoni Cuspidati was found to be the active component acting on EGFR like geﬁtinib.
There was a good relationship between their inhibiting effects on EGFR secretion and HEK293
EGFR cell growth in vitro. The EGFR/CMC-online-HPLC/MS system demonstrated fast and
effective characteristics for screening leading compounds from traditional Chinese medicine.
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Meng Sun et al.1161. Introduction
The epidermal growth factor receptor(EGFR)-mediated sig-
naling can promote the cells into a continuous and uncon-
trolled dividing state, which leads to produce more malignant
cells and augmenting tumor1. Therefore, EGFR has become
an important target for screening anti-tumor inhibitors2. Some
effective anti-EGFR drugs have been applied in clinic3–6. As
drug-targeting examples, there had an efﬁcacy and potential
prognostic value of geﬁtinib for non-small-cell lung cancer7,8
and recurrent endometrial cancer, trastuzumab for breast
cancer9,10, cetuximab for colorectal cancer in clinic treatment.
Natural medicinal plants including traditional Chinese medi-
cine are an important resource for the discovery of leading
compounds11–13. Modern pharmacological studies had shown
that traditional Chinese medicine such as Rhizoma Polygoni
Cuspidati (Huzhang in Chinese) had inhibiting effects on a
variety of malignant tumors14,15. However, little information
has been mentioned on screening active components and
investigating action domains by means of a new analytical
technique and method16,17. Cell membrane chromatography
(CMC) is a kind of bionic afﬁnity chromatography in which
the membrane receptors were prepared as cell membrane
stationary phase (CMSP)18,19. It has widely been used for
studying drug–receptor interactions and screening target
components20–23 from complex samples such as traditional
Chinese medicines24–29. In this paper, a high expression
EGFR/cell membrane chromatography and online high per-
formance liquid chromatography/mass spectrometry method
was established and used for screening active component from
Huzhang. Furthermore, the acting sites, docking extents and
biological effects of active components were also investigated.2. Materials and methods
2.1. Reagents and materials
HPLC grade methanol was purchased from Fisher Scientiﬁc
(Pittsburgh, PA, USA). Ammonium acetate was obtained
from Fuchen Chemical Reagents Factory (Tianjin, China).
Ammonia, ethanol and chloroform were obtained from Xi’an
Chemical Reagents Factory (Xi’an, China). Water was pur-
iﬁed by Chengdu Ultrapure Technology Co., Ltd. (Chengdu,
China). Silica gel (ZEX-II, 100–200 mesh) was obtained
from Qingdao Meigao Chemical Co., Ltd. (Qingdao, China).
Geﬁtinib (purity499.2%) was purchased from Nanjing Ange
Pharmaceutical Co., Ltd. (Nanjing, China). Resveratrol,
tamsulosin and nitrendipine were purchased from the
National Institute for the Pharmaceutical and Biological
Products of China (Beijing, China). RPC was purchased from
the TCM Store (Xi’an, China).
2.2. Preparation of EGFR/CMC column
The cultured EGFR cells (7 106) were washed thrice with
PBS by centrifuging at 110 g for 10 min at 4 1C. Tris–HCl
(50 mmol/L, pH¼7.4) was added to produce EGFR cell
suspension, which was ruptured by supersonic procedure for
30 min. The resulting homogenate was centrifuged at 1000 g
for 10 min. The pellet was discarded and the supernatant was
centrifuged at 12,000 g for 20 min at 4 1C. The precipitationwas suspended in 10 mL tris–HCl (50 mmol/L, pH¼7.4), and
the suspension was centrifuged at 12,000 g again. EGFR cell
membrane suspension in 5 mL distilled water was obtained.
According to the literatures, EGFR cell membrane stationary
phase (CMSP) was prepared by the adsorption of cell
membrane suspension (5 mL) on the activated silica (0.05 g)
under the vacuum and agitation conditions at 4 1C. The
EGFR CMSP was packed into the column (10 mm 2.0 mm
I.D.) using a wet packing procedure. Other chromatographic
conditions included ammonium acetate (10 mmol/L, pH¼7.4)
as a mobile phase with 0.2 mL/min ﬂow rate, UV detector and
column temperature at 3770.5 1C.
2.3. Apparatus
A high performance liquid chromatography mass spectro-
meter (HPLC/MS, Shimadzu Corporation, Kyoto, Japan)
including three LC-20AD pumps, DGU-20A3 degasser, SIL-
20A autosampler, CTO-20A column oven, SPD-20A UV/vis
detector, SPD-M20A diode array detector, LCMS2010EV
mass spectrometry and LC/MS solution workstation.
A VICIAG 10G-0911V 10-port 2-pos valve (Valco Instru-
ment Co. Inc., Houston, USA) was used as the column
switcher (CS) and two Shim-pack VP-ODS pre-columns
(10 mm 2.0 mm I.D., 5 mm, Shimadzu Corporation, Kyoto,
Japan) were used as the enrichment columns. A high expres-
sion EGFR/CMC column (10 mm 2.0 mm I.D.) was used as
the 1st D column and a Shimadzu Shim-pack VP-ODS
column (150 mm 2.0 mm I.D., 5 mm, Kyoto, Japan) as the
2nd D column.
2.4. Preparation of standard solutions
Standard stock solutions of geﬁtinib, tamsulosin and nitren-
dipine (1 mg/mL each) were separately prepared in methanol.
A mixed standards solution (0.01 mg/mL) of geﬁtinib, tamsu-
losin and nitrendipine was prepared in methanol. Standard
stock solution of resveratrol (1 mg/mL each) was prepared in
methanol. The working solutions (0.01 mg/mL) were diluted
with the mobile phase freshly.
2.5. Preparation of analytical samples
The PRC extract was obtained by following the following
procedures. 100 g dried PRC powder was extracted with 500
and 300 mL 70% ethanol twice for 2 h each time. The solvents
were combined and recovered to obtain 2.7 g PRC extract.
Sample solution of PRC extract (1 mg/mL each) was
prepared in methanol, and stored at 4 1C in dark. The working
solution (0.1 mg/mL) was diluted with a mobile phase freshly.
2.6. Operating conditions
HPLC conditions include a VP-ODS column (150 mm
2.0 mm I.D., 5 mm), a mobile phase of methanol–water–
0.1% ammonia (55:45, v/v) with 0.2 mL/min ﬂow rate and
column temperature at 37 1C. MS conditions are given as
follows: nebulizer gas (N2, purity499.999% ) ﬂow rate, 1.5
L/min; drying gas (N2, purity499.999%) pressure, 0.1 MPa;
interface temperature, 250 1C; heat block temperature, 200 1C;
detector voltage, 1.25 kV.
Development of a system for screening EGFR antagonists 117The EGFR/CMC model was combined with HPLC/MS by
means of a 10-port column switcher in an online way. Each
sample was injected into the EGFR/CMC model, and then the
elution curve (C1D) of each sample was recorded and related
fractions were switched onto two ODS pre-columns (PC1 and
PC2) at the same time. Each enriched fraction was successively
eluted into the HPLC/MS system for analysis, and HPLC/MS
chromatograms (C2D) of each fraction were obtained.
2.7. Analysis of samples
This EGFR/CMC-online-HPLC/MS system was applied for
screening EGFR antagonists in geﬁtinib as a control drug.
The standard solution and PRC extract prepared above were
analyzed.
2.8. Cell growth assay
The effect of resveratrol on EK293/EGFR viability was
evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay. Brieﬂy, exponentiallyFigure 1 Chromatograms of standard solution and RPC extract u
chromatogram of the mixed standards solution (Cs); EGFR/CMC ch
enriched by CS and analyzed by HPLC/MS as geﬁtinib (g), and R0
(b) HPLC/MS chromatogram of RPC extract (Cs). EGFR/CMC chro
RPC extract on EGFR/CMC and enriched by CS and were analyzed b
R1-1 of R1 fraction was identiﬁed as resveratrol (r). (c) HPLC/MS ch
chromatogram of resveratrol standard solution (C1D); HPLC/MS chr
identiﬁed as resveratrol (r).growing cells were harvested and plated in 96-well plates at
a concentration of 1 104 cells/well. After 24 h incubation at
37 1C, cells were treated with resveratrol at various concentra-
tions for 48 h. Then, 20 mL of MTT (5 mg/mL) was added to
each well and incubated at 37 1C for 4 h. After the supernatant
was discarded, 150 mL of DMSO was added to each well, and
the optical density of cells was determined with a microplate
reader (Bio-RAD Instruments, USA) at 490 nm and expressed
as absorbance values30.2.9. Western blot analysis
The HEK293/EGFR cells treated with resveratrol for 48 h
were prepared by extracting proteins with RIPA lysis buffer
containing protease inhibitor cocktail and phosphatase inhi-
bitor cocktail (Roche, Switzerland) on ice. The epidermal
growth factor (EGF) was added in the cell culture medium for
15 min before extracting proteins. Protein concentration was
determined by BCA protein quantitation kit according to the
manufacturer’s instructions. Proteins were resolved by SDS-
polyacrylamide gel electrophoresis (PAGE) loading 30 mL ofsing an EGFR/CMC-online-HPLC/MS method. (a) HPLC/MS
romatogram of the mixed standards solution (C1D); R1 fraction
fraction identiﬁed as tamsulosin (t) and nitrendipine (n) (C2D).
matogram of RPC extract (C1D); R0 and R1 are the fractions of
y HPLC/MS, the chromatograms were recorded as C2D. The peak
romatogram of resveratrol standard solution (Cs). EGFR/CMC
omatogram of R1 fraction (C2D), and the retention peak (R1) was
Meng Sun et al.118cell lysates per lane. After electrophoresis, separated proteins
were transferred to nitrocellulose membrane and blocked by
5% non-fat milk in TBST buffer for 2 h. After then, the
membranes were incubated with primary antibodies (anti-Erk,
anti-phospho-Erk and anti-b-action were used as primary
antibodies) at 1:1000 dilutions in 5% non-fat milk overnight
at 4 1C with continuous agitation, and then secondary anti-
bodies conjugated with horseradish peroxidase at 1:5000
dilution for 2 h at room temperature according to the
manufacturer’s recommended protocol31. Finally, the blots
were detected by enhanced chemiluminescence (ECL) reagent
(Amersham Pharmacia Biotechnology, USA) and analyzed
using Quantity ones, 1D analysis software (Version 4.4,
Bio-Rad, USA).3. Results and discussion
3.1. Reliability of the EGFR/CMC-online-HPLC/MS system
The EGFR/CMC-online-LC/MS system developed in this
study was suitable for qualitative analysis of active compo-
nents from the complex samples. The brief scheme of the
system has been demonstrated in our previous work25,26. In
this system, the components were recognized by the EGFR/
CMC model and then identiﬁed by the HPLC/MS from aFigure 2 Inhibitory effects of resveratrol on HEK293/EGFR cell.
dependent inhibition of HEK293/EGFR cell viability by resveratrol. (
the expression of Erk and P-Erk proteins in HEK293/EGFR cells.
collected and lysed. Western blot analysis was conducted and p
corresponded to Erk, P-Erk and b-action. Results were quantiﬁed by d
to b-action protein. (c) Erk and P-Erk. Values are expressed as meancomplex sample in an online way. A mixed standard solution
containing geﬁtinib, tamsulosin and nitrendipine was used to
verify the selectivity of the EGFR/CMC-online-HPLC/MS
system (Fig. 1a). Of the three standards, only geﬁtinib is
selectively acting on EGFR. The chromatogram of the mixed
standard solution on EGFR/CMC is presented in Fig. 1a C1D.
Two fractions (indicated by dotted lines) were sequentially
extracted onto pre-columns and then switched onto column
CODS for chromatographic separation (Fig. 1a C2D) and MS
identiﬁcation. This experiment demonstrated that geﬁtinib was
speciﬁcally retained by the EGFR/CMC system from the
solution of mixed standards and could be simultaneously
analyzed by HPLC/MS.
3.2. Applications
This system was used for screening active components from
traditional Chinese medicines such as RPC. Chromatograms
of the RPC extract obtained using the EGFR/CMC-online-
LC/MS method are shown in Fig. 1b. The retention fraction
(R1) in the EGFR/CMC model (Fig. 1b C1D), and the fraction
was assayed using the LC/MS system online for further
separation and identiﬁcation. As shown in Fig. 1b C2D, the
main component of the R1 fraction (peak R1-1) was identiﬁed
as resveratrol. Compared with Fig. 2b CS, resveratrol can be
identiﬁed from the RPC extract.(a) Effects of resveratrol on the cell growth. There was a dose-
b) Effects of Erk and P-Erk by resveratrol. Resveratrol regulated
Cells were treated with 0, 0.40, 10.0 mmol/L for 48 h. Cells were
robed with anti-Erk and anti-P-Erk and anti-b-action. Bands
ensitometry analysis of the bands from (b) and then normalization
7SD (n¼5). nnPo0.01 vs. control.
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solution was analyzed using the EGFR/CMC-online-LC/MS
method. The standard solution of resveratrol (0.01 mg/mL)
was injected into the EGFR/CMC model. As shown in
Fig. 1c, the main retention fraction in the EGFR/CMC model
was identiﬁed as resveratrol.
3.3. Biological trials
In this method, the EGFR/CMC model that used high EGFR
expression EGFR cell membrane as stationary phase can
selectively recognize EGFR antagonists such as geﬁtinib.
Geﬁtinib was also used as a control drug for the biological
activity of the cellular level veriﬁcation. MTT results showed
that resveratrol measured by high expression of EGFR-
dependent manner inhibited cell proliferation (Fig. 2a) and
phosphorylation (Fig. 2b), as well as effectively reduced the
downstream signaling molecules (Fig. 2c) expression and
blocked signal transduction.4. Conclusions
EGFR/CMC-online-HPLC/MS system, the use of high
expression of EGFR/CMC model, increasing the target
component ‘identiﬁcation’ of the selectivity and sensitivity,
online in conjunction with the HPLC/MS identiﬁcation
enhancing the system’s qualitative features, is a complex
system from the lead compounds in drug discovery for the
fast and effective screening system.
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